News & Events zu MoonLake Immunotherapeutics (MLTX)MLTXMoonLake Immunotherapeutics

MoonLake Holds $537M in Cash and Short-Term Debt

MoonLake held cash, cash equivalents and short-term marketable debt securities of $537M. The company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to mid-2028. MoonLake's debt facility with Hercules Capital provides up to $400M in additional non-dilutive funds to support potential future funding needs

MoonLake Reports Positive Results from IZAR-1 Trial

MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naive adults with active psoriatic arthritis. The IZAR Phase 3 program consists of two registrational global randomized, double-blind trials, IZAR-1 and IZAR-2, designed to evaluate the efficacy and safety of sonelokimab in adults with active psoriatic arthritis. IZAR-1 is being conducted in biologic-naive adults with active PsA. Following the Week 16 primary endpoint analysis, patients will continue participating in their respective studies through Week 52 to evaluate the durability of efficacy and safety of sonelokimab. The primary endpoint of IZAR-1 is the percentage of patients achieving an American College of Rheumatology 50 response at Week 16. Key secondary clinical endpoints evaluate the broad multidomain efficacy of sonelokimab across musculoskeletal, skin, patient-reported and physical outcomes and include the percentage of patients achieving an ACR20 response, Minimal Disease Activity, and Psoriasis Area and Severity Index 90 response, as well as changes from baseline in the Health Assessment Questionnaire Disability Index and SF-36 Physical Component Summary score. The Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 for 60 mg sonelokimab. Consistent with the unblinding protocol defined with the FDA, topline disclosure at Week 16 includes absolute response levels and endpoint outcomes for the sonelokimab 60 mg with induction arm. Comparative analyses versus placebo and detailed treatment arm data remain blinded until completion of the Phase 3 program. A total of 42.1% of biologic-naive patients treated with sonelokimab 60 mg with induction achieved an ACR50 response. In addition, sonelokimab demonstrated strong efficacy across multiple disease domains characteristic of PsA. Across key secondary clinical endpoints, 66.5% of patients achieved ACR20, and 41.2% achieved MDA at Week 16. In patients with concomitant skin involvement, 61% achieved PASI90 at Week 16. Patients treated with sonelokimab also demonstrated clinically meaningful improvements in patient-reported and physical outcomes. Mean change from baseline in HAQ-DI was -0.427, while improvements were observed in SF-36 Physical Component Summary with a score of 6.54. IZAR-1 does not include a Standard of Care arm as ARGO had provided data in such context for the Bio-Naive population. IZAR-2 will provide data in comparison with a Standard of Care in TNF-refractory patients. The blinded safety analysis of IZAR-1 suggests a profile consistent with previous clinical studies and no new safety signals were observed. In addition, the drop-out rate of IZAR-1 until Week 16 is low and in line with other trials in PsA.

MoonLake Shares Drop 11% After Q2 Earnings

MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results